Skystar Bio-Pharmaceutical Company (SKBI) 0.2300 $
Post# of 273257
Posted On: 09/03/2016 7:22:20 PM
Skystar Bio-Pharmaceutical Company (SKBI) 0.2300 $SKBI
Skystar Bio-Pharmaceutical Company Update
Marketwired - Tue Dec 22, 9:17AM CST
Skystar Bio-Pharmaceutical Company (OTCQB: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that while the Company trades on the over-the-counter market, it has made progress with its audits.
Skystar Bio-Pharmaceutical Company Announces Delisting From NASDAQ
Marketwired - Fri Dec 18, 3:30PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that on December 17, 2015, Skystar Bio-Pharmaceutical Company (the "Company"
received notification from The Nasdaq Stock Market ("Nasdaq" informing the Company that a Nasdaq hearing panel had decided to delist the Company's shares from Nasdaq and that the Company's shares would be suspended from trading on Nasdaq at the open of business on December 21, 2015.
Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Notification Letter
Marketwired - Thu Nov 19, 10:57AM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that on November 17, 2015, it received a letter from NASDAQ Stock Market indicating that that Skystar failed to comply with Nasdaq's filing requirement set forth in Listing Rule 5250(c)(1) (the "Rule" because it failed to file its Form 10-Q for the fiscal quarter ended September 30, 2015 (the "Quarterly Report".
Skystar Bio-Pharmaceutical Company Request to Stay Nasdaq Trading Suspension Granted
Marketwired - Fri Nov 06, 8:00AM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that on November 4, 2015 it received a letter from the Nasdaq Hearings Panel that granted the request of Skystar Bio-Pharmaceutical Company to extend the automatic 15-day stay of suspension from The Nasdaq Stock Market, until the hearing on the merits scheduled for December 3, 2015, and a determination regarding the Company's listing status.
Skystar Bio-Pharmaceutical Company Provides Investor Update Regarding Delay in Filing Form 10-K
Marketwired - Fri Oct 02, 8:30AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (the "Company", a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that it has conferred with Crowe Horwath, HK, the Company's appointed auditor in relation to the completion of Skystar's audit for the year ended December 31, 2014 and the review of the Company's financial statements for the quarters ended March 31, 2015 and June 30, 2015. Based on those communications, Skystar believes that Crowe Horwath is in the process of completing its audit of the Company's financial statements for the year ended December 31, 2014.
Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Non-Compliance Letter Due to Delay in Filing Form 10-Q
Marketwired - Tue Aug 25, 3:15PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (the "Company", a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that on August 19, 2015, the Company received a notification from the Nasdaq Stock Market ("Nasdaq" informing the Company that because it had not filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Company previously submitted a plan of compliance to Nasdaq, responded to an initial request for additional information from Nasdaq, and is preparing responses to a second request for additional information from Nasdaq. If its plan is approved by the Nasdaq staff, the Company may be eligible for a listing exception of up to 180 calendar days from the date of its initial delinquent filing (its Annual Report on Form 10-K for the year ended December 31, 2014), or until October 12, 2015, to regain compliance.
Skystar Bio-Pharmaceutical Company Announces Submission of Plan of Compliance With Nasdaq
Marketwired - Mon Jun 15, 9:32PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (the "Company", a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company timely submitted a "Plan of Compliance" to Nasdaq in accordance with applicable Nasdaq rules. The Plan of Compliance sets out the Company's plan to regain compliance with Nasdaq's continued listing rules.
Skystar Bio-Pharmaceutical Company Announces Receipt of NASDAQ Non-Compliance Letter Due to Delay in Filing Form 10-K
Marketwired - Wed Apr 15, 4:00PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company received a notification from the Nasdaq Stock Market ("Nasdaq" informing the Company that since it had not filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2014, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted under its current trading symbol.
Skystar Bio-Pharmaceutical Reports Third Quarter Fiscal Year 2014 Financial Results
Marketwired - Fri Nov 14, 4:01PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company", a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today reported unaudited third quarter fiscal year 2014 earnings, for the period ended September 30, 2014.
Skystar Bio-Pharmaceutical Company Update
Marketwired - Tue Dec 22, 9:17AM CST
Skystar Bio-Pharmaceutical Company (OTCQB: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that while the Company trades on the over-the-counter market, it has made progress with its audits.
Skystar Bio-Pharmaceutical Company Announces Delisting From NASDAQ
Marketwired - Fri Dec 18, 3:30PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that on December 17, 2015, Skystar Bio-Pharmaceutical Company (the "Company"
received notification from The Nasdaq Stock Market ("Nasdaq" informing the Company that a Nasdaq hearing panel had decided to delist the Company's shares from Nasdaq and that the Company's shares would be suspended from trading on Nasdaq at the open of business on December 21, 2015. Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Notification Letter
Marketwired - Thu Nov 19, 10:57AM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that on November 17, 2015, it received a letter from NASDAQ Stock Market indicating that that Skystar failed to comply with Nasdaq's filing requirement set forth in Listing Rule 5250(c)(1) (the "Rule"
because it failed to file its Form 10-Q for the fiscal quarter ended September 30, 2015 (the "Quarterly Report". Skystar Bio-Pharmaceutical Company Request to Stay Nasdaq Trading Suspension Granted
Marketwired - Fri Nov 06, 8:00AM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that on November 4, 2015 it received a letter from the Nasdaq Hearings Panel that granted the request of Skystar Bio-Pharmaceutical Company to extend the automatic 15-day stay of suspension from The Nasdaq Stock Market, until the hearing on the merits scheduled for December 3, 2015, and a determination regarding the Company's listing status.
Skystar Bio-Pharmaceutical Company Provides Investor Update Regarding Delay in Filing Form 10-K
Marketwired - Fri Oct 02, 8:30AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (the "Company"
, a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that it has conferred with Crowe Horwath, HK, the Company's appointed auditor in relation to the completion of Skystar's audit for the year ended December 31, 2014 and the review of the Company's financial statements for the quarters ended March 31, 2015 and June 30, 2015. Based on those communications, Skystar believes that Crowe Horwath is in the process of completing its audit of the Company's financial statements for the year ended December 31, 2014. Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Non-Compliance Letter Due to Delay in Filing Form 10-Q
Marketwired - Tue Aug 25, 3:15PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (the "Company"
, a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that on August 19, 2015, the Company received a notification from the Nasdaq Stock Market ("Nasdaq" informing the Company that because it had not filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Company previously submitted a plan of compliance to Nasdaq, responded to an initial request for additional information from Nasdaq, and is preparing responses to a second request for additional information from Nasdaq. If its plan is approved by the Nasdaq staff, the Company may be eligible for a listing exception of up to 180 calendar days from the date of its initial delinquent filing (its Annual Report on Form 10-K for the year ended December 31, 2014), or until October 12, 2015, to regain compliance. Skystar Bio-Pharmaceutical Company Announces Submission of Plan of Compliance With Nasdaq
Marketwired - Mon Jun 15, 9:32PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (the "Company"
, a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company timely submitted a "Plan of Compliance" to Nasdaq in accordance with applicable Nasdaq rules. The Plan of Compliance sets out the Company's plan to regain compliance with Nasdaq's continued listing rules. Skystar Bio-Pharmaceutical Company Announces Receipt of NASDAQ Non-Compliance Letter Due to Delay in Filing Form 10-K
Marketwired - Wed Apr 15, 4:00PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company received a notification from the Nasdaq Stock Market ("Nasdaq"
informing the Company that since it had not filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2014, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted under its current trading symbol. Skystar Bio-Pharmaceutical Reports Third Quarter Fiscal Year 2014 Financial Results
Marketwired - Fri Nov 14, 4:01PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"
, a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today reported unaudited third quarter fiscal year 2014 earnings, for the period ended September 30, 2014. 
(0)
(0)Scroll down for more posts ▼